SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

“Hmmm” is a community meme token on the Solana network, launched on July 22, 2024, through Pumpfun. It’s a derivative of Pepe the Frog but has evolved into its own distinct meme with a unique identity. The token embraces the humor and intrigue of internet culture, playing on the idea of curiosity and speculation. “Hmmm” captures a playful approach to the world of meme tokens, designed to engage a community driven by fun and the whimsical side of crypto. Hmmm, maybe this’ll send.

hmmm

The crypto token $HMMM is gaining attention, with many users discussing its potential and availability on Phantom Wallet. Community members are using terms like "rocket," "moon," and "gem" to describe the token's momentum. Some users are also speculating about the driving forces behind the recent price action.

Clanker is an autonomous agent for deploying tokens. Currently, users may request clanker to deploy an ERC-20 token on Base by tagging it @clanker on Farcaster.

tokenbot

Clanker Crypto ($CLANKER) is trending due to its recent listing and small circulating supply, leading to volatile price action and community speculation about potential for rapid gains. Some users are reporting issues with trading on Coinbase, while others point to AI tools and broader market trends as potential catalysts. The token's limited supply of one million is a key talking point, with many anticipating significant price movement if it gains further attention.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as traders discuss its low market cap and circulating supply, anticipating a potential breakout. Some community members point to its integration with Aleph Zero, while others speculate about possible listings on major exchanges like Binance as a catalyst for significant gains. Technical analysis chatter includes mentions of oversold RSI conditions and bull flag formations.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending as the community debates its future following FDA approval of Tonmya, with discussions focused on potential sales, upcoming catalysts, and whether the stock is undervalued. Some traders express frustration with management and the stock's performance, while others remain optimistic about long-term growth and potential short squeezes. BlackRock's increased stake is being viewed as a potential bullish signal amid the ongoing volatility.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is gaining traction as a community-driven token with viral hype, trending on Stocktwits with serious volume. The community emphasizes its strength and unity, rallying behind upcoming events like Karolina Arm's sponsored fight. Discussions highlight $SLAP's ambition to become a global brand, transcending its meme origins through real-world partnerships and a dedicated community.

Columbus Circle Capital Corp. I operates as a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which refer to throughout this prospectus as initial business combination. The company was founded in June 2024 and is headquartered in New York, NY.

Columbus Circle Capital Corp I - Ordinary Shares - Class A

Columbus Circle Capital ($BRR) is trending as the community discusses Eric Jackson joining the board and anticipates a potential pump, drawing comparisons to past option surges. Chatter revolves around upcoming call options and a proposed merger with ProCap BTC, with some seeing a potentially favorable risk-reward scenario due to the SPAC's NAV floor. Recent news includes updates to the merger agreement and the appointment of a new CFO.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending amid discussions about its role in bridging blockchain technology with gaming, offering players ownership of digital assets and powering tokenized economies. Community members are actively discussing its potential in the expanding play-to-earn and virtual world sectors, as well as new exchange listings. Some traders are pointing out that the altcoin is closely related to Base, a layer-2 network that is built on top of the Ethereum blockchain.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Biogen ($BIIB) is trending due to news of a potential shakeup in the Alzheimer's space following a recent investment in Vanqua Bio, which has investors speculating about Biogen's strategy around C5aR1 inhibitors, a target also being pursued by InflaRx ($IFRX). The community is analyzing the implications of Biogen's move for InflaRx's valuation and potential acquisition, viewing it as both mechanistic validation and a catalyst for sentiment. There is also discussion around Biogen's earnings and growth prospects, especially concerning new therapies offsetting multiple sclerosis portfolio weakness.

KraneShares Trust - KraneShares Global Humanoid and Embodied Intelligence Index ETF

KraneShares Global Humanoid and Embodied Intelligence Index ETF

$KOID is trending as discussions emerge around robotics and AI, specifically humanoid robots. Community members are actively comparing $KOID to other robotics ETFs and discussing the potential impact of Chinese investment in the sector, with some noting the fund's growing exposure and potential for long-term growth. Mentions of Elon Musk's views on robotics and humanoid development are also contributing to the conversation.

Tidal Trust II - YieldMax NVDA Option Income Strategy ETF

YieldMax NVDA Option Income Strategy ETF

NVDY is trending as investors discuss its dividend payouts and overall performance relative to its underlying asset, NVDA. The community is debating whether the ETF's returns justify its risks, especially given recent fluctuations in dividend yields and NAV. Some traders express disappointment with payout amounts, while others remain optimistic about its income-generating potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition

Alkermes inks $2.1B deal to acquire Avadel, adding the latter's Lumryz and new growth potential to its portfolio.

How Much Upside is Left in Castle Biosciences (CSTL)? Wall Street Analysts Think 50.08%

The consensus price target hints at a 50.1% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

What Makes Castle Biosciences (CSTL) a New Strong Buy Stock

Castle Biosciences (CSTL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates

Castle Biosciences (CSTL) delivered earnings and revenue surprises of +129.41% and +16.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for August 1st

CRSP, CSTL and SIGI have been added to the Zacks Rank #5 (Strong Sell) List on August 1, 2025.

TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release

TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline

Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Castle Biosciences to Participate in Upcoming Investor Conferences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company...

Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share data supporting its dermatologic portfolio of gene expression profile...

Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter...

Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Castle Biosciences Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.52	--	--	N/A
Q2 '25	-$0.53	$0.15	128.24%	BEAT
Q1 '25	-$0.07	-$0.90	-1195.95%	MISSED
Q4 '24	$0.05	$0.32	579.25%	BEAT
Q3 '24	-$0.00	$0.08	2091.54%	BEAT

CSTL
Castle Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest CSTL News

CSTLCastle Biosciences Inc